ERJ Open Research (Aug 2021)

International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives

  • June K. Marthin,
  • Jane S. Lucas,
  • Mieke Boon,
  • Carmen Casaulta,
  • Suzanne Crowley,
  • Damien M.S. Destouches,
  • Ernst Eber,
  • Amparo Escribano,
  • Eric Haarman,
  • Claire Hogg,
  • Bernard Maitre,
  • Gemma Marsh,
  • Vendula Martinu,
  • Antonio Moreno-Galdó,
  • Huda Mussaffi,
  • Heymut Omran,
  • Petr Pohunek,
  • Bernhard Rindlisbacher,
  • Phil Robinson,
  • Deborah Snijders,
  • Woolf T. Walker,
  • Panayiotis Yiallouros,
  • Helle Krogh Johansen,
  • Kim G. Nielsen

DOI
https://doi.org/10.1183/23120541.00301-2021
Journal volume & issue
Vol. 7, no. 3

Abstract

Read online

Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway infections and progressive lung destruction, and concern over chronic airway infection and patient-to-patient transmission is considerable. So far, there has been no defined consensus on how to control infection across centres caring for patients with PCD. Within the BEAT-PCD network, COST Action and ERS CRC together with the ERN-Lung PCD core a first initiative has now been taken towards creating such a consensus statement. Methods A multidisciplinary international PCD expert panel was set up to create a consensus statement for infection prevention and control (IP&C) for PCD, covering diagnostic microbiology, infection prevention for specific pathogens considered indicated for treatment and segregation aspects. Using a modified Delphi process, consensus to a statement demanded at least 80% agreement within the PCD expert panel group. Patient organisation representatives were involved throughout the process. Results We present a consensus statement on 20 IP&C statements for PCD including suggested actions for microbiological identification, indications for treatment of Pseudomonas aeruginosa, Burkholderia cepacia and nontuberculous mycobacteria and suggested segregation aspects aimed to minimise patient-to-patient transmission of infections whether in-hospital, in PCD clinics or wards, or out of hospital at meetings between people with PCD. The statement also includes segregation aspects adapted to the current coronavirus disease 2019 (COVID-19) pandemic. Conclusion The first ever international consensus statement on IP&C intended specifically for PCD is presented and is targeted at clinicians managing paediatric and adult patients with PCD, microbiologists, patient organisations and not least the patients and their families.